LinkedIn Icon Twitter Icon
Dates TBC (March 2019) | Boston, MA

Day One
Tuesday, March 20 2018

Day Two
Wednesday, March 21 2018

08.20
Chair’s Opening Remarks

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center

Pioneering Rational Combination Approaches

08.30
Keynote: Enhancing Patient Outcomes With Pembrolizumab In Combination Strategies

  • Roger Dansey SVP, Global Clinical Development Oncology, Merck

Synopsis

  • Investigating diverse combination strategies with pembrolizumab
  • Critical considerations for developing effective combination strategies – improving outcomes and maintaining tolerability
  • Understanding clinical combinations: biologic rationale and expecting the unexpected

09.00
Keynote: Addressing the Tidal Wave of Cancer Immunotherapy Combinations Through Innovative Trial Designs

  • Edward Cha Medical Director, Cancer Immunotherapy Franchise, Genentech

Synopsis

  • Highlighting the opportunity for novel clinical trial designs to address developmental challenges in the cancer immunotherapy space
  • Investigating the current state of cancer immunotherapy combination development across the industry
  • Understanding key clinical development challenges for cancer immunotherapy combination development
  • Developing a combination platform to increase the speed of identification of transformative signals
  • Examples of novel clinical trial designs to address combination development challenges

09.30
Predicting Marketed PD-1 Dosing and Optimal PD-1 x TIM-3 Dual Targeting Approaches in Immuno-Oncology

  • John Burke Co-Founder, President & CEO , Applied BioMath

Synopsis

Developing and interrogating a systems pharmacology model provides early quantitative decision making guidance for project teams.  In this presentation we will look at how interrogating a systems pharmacology model of the co-modulation inhibitory receptors PD-1 and TIM-3 in immuno-oncology helped to:

  • Assess risk by performing an in silico differentiation for a bispecific vs. FDC
  • Analyze why BMS and Merck anti-PD-1s therapeutic antibodies have similar dosing regimens when their affinities differ by two orders of magnitude
  • Provide predictions of the best-in-class profile for a PD-1 and TIM-3 dual antagonist biologic(s)

10.00
Speed Networking & Morning Refreshments

15.00
Afternoon Refreshments & Poster Viewing

Turning Up the Heat on Cold Tumors by Engaging the Broader Tumor Microenvironment

16.00
Presentation details to be confirmed

  • James Keck Senior Director, In Vivo Pharmacology, The Jackson Laboratory

16.30
Evaluating the Role of Stromal Cells & TGFβ Signalling in the Resistance to Atezolizumab

Synopsis

  • Understanding the role of stromal cells in the tumor microenvironment and the effect of cross-talk with immune cells
  • Analyzing factors correlating with resistance to atezolizumab and reverse translating this information to provide meaningful preclinical insights
  • Building tools to study mesenchymal cells and their impact on immuno-oncology across tumor types

17.00
Chair’s Closing Remarks

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center